Clinical Report: Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

Overview

A modeling study suggests that gene therapy for sickle cell disease could be cost-effective in Uganda if prices are significantly reduced. The analysis indicates that Casgevy may be a more viable option compared to Lyfgenia when considering local treatment costs and societal benefits.

Background

Sickle cell disease (SCD) poses a significant health burden, particularly in low-income countries like Uganda. Current treatment costs in Uganda are substantially lower than in high-income countries, highlighting the potential for cost-effective interventions. Understanding the economic viability of gene therapy in such settings is crucial for expanding access to innovative treatments.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Gene therapy for SCD could be cost-effective in Uganda if prices are reduced.
• Casgevy is identified as a more viable gene therapy option compared to Lyfgenia based on cost-effectiveness ratios.
• Uganda's lifetime standard-of-care cost for SCD is estimated at $21,877, significantly lower than over $600,000 in the U.S.
• Societal benefits, such as increased productivity and reduced caregiver burden, are important factors in cost-effectiveness analysis.
• The study provides a framework for policymakers to assess the economic impact of gene therapies in low-resource settings.

Clinical Implications

Healthcare professionals should consider the economic context when evaluating gene therapy options for SCD in low-income settings. Policymakers may need to advocate for price reductions to enhance access to effective treatments like Casgevy.

Conclusion

The findings underscore the importance of adapting high-income health economic models to low-income contexts to facilitate access to innovative therapies. Continued efforts are needed to ensure equitable access to gene therapy for SCD in regions with high disease burden.

References

1. The ASCO Post, 2019 -- Pilot Study Tests Novel Approach to Gene Therapy for Sickle Cell Disease
2. Retinal Physician, 2023 -- UPFRONT: Gene Therapy's Price Tag
3. The Medicine Maker, 2026 -- CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
4. Bone Marrow Transplantation -- Understanding Gene Addition and Editing Strategies for Sickle Cell Disease
5. American Society of Hematology, 2021 -- Guidelines for Sickle Cell Disease: Stem Cell Transplantation
6. FDA, 2023 -- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
7. SCDAA, 2023 -- Statement About Gene Therapy Approval
8. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation | Blood Advances | American Society of Hematology
9. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA
10. SCDAA Statement About Gene Therapy Approval - Sickle Cell Disease Association of America Inc.